Ganciclovir Injection, Powder, Lyophilized, For Solution
Product Images NDC 70436-089

5 FDA label images from Slate Run Pharmaceuticals, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ganciclovir (NDC 70436-089). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

T:\spl Documents\ganciclovir Injection-spl\chemical Structures.jpg (Chemical Structures)

T:\spl Documents\ganciclovir Injection-spl\chemical Structures.jpg (Chemical Structures)
Chemical structures of ganciclovir sodium and ganciclovir are shown side-by-side. Each structure includes labeled molecular formulas and molecular weights: ganciclovir sodium (C9H12N5NaO4, MW 277.22) and ganciclovir (C9H13N5O4, MW 255.23). The structures depict the arrangement of atoms and bonds in each molecule.*
FDA Label Image

T:\spl Documents\ganciclovir Injection-spl\figure 1 Pan Black C.jpg (Figure 1 Pan Black C)

T:\spl Documents\ganciclovir Injection-spl\figure 1 Pan Black C.jpg (Figure 1 Pan Black C)
A line graph titled 'ICM 1653: Time to Progression of CMV Retinitis' showing the proportion of patients without disease progression over time in days from the start of maintenance therapy. The graph compares two treatments labeled 'IV' (intravenous) with a dashed line and 'Oral' with a solid line, depicting changes in progression rates up to 150 days.*
FDA Label Image

T:\spl Documents\ganciclovir Injection-spl\figure 2 Pan Black C.jpg (Figure 2 Pan Black C)

T:\spl Documents\ganciclovir Injection-spl\figure 2 Pan Black C.jpg (Figure 2 Pan Black C)
A line chart titled 'ICM 1774: Time to Progression of CMV Retinitis' comparing the proportion without progression over time from the start of maintenance therapy (days) up to 120 days. It includes two lines: a dashed line representing IV and a solid line representing Oral, showing decreasing proportion without progression over time.*
FDA Label Image

T:\spl Documents\ganciclovir Injection-spl\figure 3 Pan Black C.jpg (Figure 3 Pan Black C)

T:\spl Documents\ganciclovir Injection-spl\figure 3 Pan Black C.jpg (Figure 3 Pan Black C)
A line graph titled 'AVI 034: Time to Progression of CMV Retinitis' showing the proportion of patients without progression over time in days from the start of maintenance therapy. Two curves are plotted: a dashed line for intravenous (IV) therapy and a solid line for oral therapy, both declining over approximately 150 days.*
FDA Label Image

Ganciclovir For Injection, Usp 500 mg Vial (Image 01)

Ganciclovir For Injection, Usp 500 mg Vial (Image 01)
Chemical structures of ganciclovir sodium and ganciclovir are shown, each with their respective molecular formulas and molecular weights. Ganciclovir sodium has the formula C9H12N5NaO4 and a molecular weight of 277.22, while ganciclovir has the formula C9H13N5O4 and a molecular weight of 255.23.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.